PD02.05. Long-Term Incidence and Treatment Outcomes of Gastric Conduit Cancer After Esophagectomy

Clicks: 2
ID: 325721
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #408 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Other Background Gastric conduit cancer (GCC), a primary carcinoma arising in the reconstructed gastric conduit after esophagectomy, is rare, and its true incidence and long-term outcomes remain unclear. We aimed to determine its cumulative incidence and treatment-related outcomes. Methods We retrospectively reviewed 4,490 patients who underwent esophagectomy with gastric conduit reconstruction between 1994 and August 2025. Among them, 93 developed GCC during follow-up. Clinical characteristics and treatment outcomes of these patients were analyzed. Results The cumulative incidence of GCC was 2.22% at 10 years and 3.16% at 20 years, with a median interval of 48.2 months (IQR, 26.0–94.1) from esophagectomy to diagnosis. All tumors were adenocarcinomas. Surgical resection was performed in 14 patients (take-down of gastric conduit and colon interposition, n=11; partial gastrectomy or wedge resection, n=3) without postoperative mortality, with a median event-free survival (EFS) of 107.9 months and a 5-year EFS of 77.9%. Endoscopic therapy was the most common treatment (n=64; endoscopic submucosal dissection (ESD), n=62; argon plasma coagulation, n=2), with a median EFS of 56.4 months and a 5-year EFS of 48.2%; two patients required salvage surgery, and seven experienced recurrence at a median of 30.9 months. Eight patients received radiation therapy / concurrent chemoradiation therapy (median EFS 83.0 months; 5-year EFS 60.0%), and eight underwent chemotherapy or palliative care (median EFS 11.1 months; 5-year EFS 0%). Conclusion GCC remains a clinically significant long-term complication after esophagectomy. Endoscopic therapy offers favorable outcomes for early-stage disease, whereas advanced-stage GCC carries a poor prognosis. Therefore, structured and lifelong endoscopic surveillance is crucial for early detection and for improving long-term survival after esophagectomy.
Reference Key
openalex_W7203907576 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hyun Ki Jeong, Sung Yong Park, Tae Se Kim, Yang Won Min, Dong Ryul Oh, S. Park, Jong Mu Sun, Yeong Jeong Jeon, Jung Hee Lee, Jong Ho Cho, Hong Kwan Kim, Yong Soo Choi
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.083
URL
https://doi.org/10.1093/dote/doag077.083
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.